GLP-1RA-based agents represent a potential strategy for treating both MASLD and T2D.35 GLP-1RAs lead to a reduction in leptin, resistin and monocyte chemoattractant protein-1 and increase adiponectin levels, which inhibit lipolysis and reduce fat mass. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.